Takeda Pharmaceutical Company (4502) Q2 2025 earnings summary

Executive summary

• H1 FY2024 revenue grew 13.4% year-over-year to JPY 2,384.0 billion (+5.0% at CER), driven by 18.7% growth in launch products, now 47% of total revenue.

• Core operating profit margin reached 30.2% in H1, benefiting from product mix, R&D phasing, and efficiency programs; reported operating profit surged 194% due to lower non-core items.

• Major launches (Fruzaqla, Adzynma, Eohilia) exceeded expectations, with rapid uptake and expanded approvals across key markets.

• Vyvanse experienced slower-than-expected erosion in H1 but is expected to accelerate in H2, impacting revenue and profit.

• Efficiency program implementation is on track, targeting 100–250bps annual margin improvement from FY2025.

Financial highlights

• H1 FY2024 revenue: JPY 2,384.0B (+13.4% actual, +5.0% CER); core operating profit: JPY 719.9B (+22.3% actual, +12.9% CER); margin 30.2%.

• Net profit attributable to owners: JPY 187.3B (+352.8% year-over-year); core EPS: 310 yen (+18.8%); reported EPS: 119 yen.

• Adjusted free cash flow: JPY 247.5B (vs. -71.1B prior year); operating cash flow: JPY 451.3B (+54.9%).

• Interim dividend set at JPY 98 per share; annual dividend projection maintained at JPY 196 per share.

• Q2 FY2024 revenue: JPY 1,176.0B (+12.7% actual, +8.0% CER); core operating profit: JPY 337.7B (+28.7% margin).

Outlook and guidance

• FY2024 revenue forecast raised to JPY 4,480.0B; core operating profit to JPY 1,050.0B; core EPS to 456 yen; annual dividend plan confirmed at 196 yen per share.

• Management guidance at CER: core revenue expected flat to slightly increasing, core operating profit mid-single-digit % decline, core EPS approx. 10% decline.

• Guidance reflects continued product momentum, especially Vyvanse, and updated FX assumptions (JPY/USD 150, JPY/EUR 165).

• H2 assumes acceleration of Vyvanse generic erosion and increased R&D investment, with expenses more heavily weighted to H2.

• Free cash flow forecast raised; FX positive for revenue but negative for core OP due to euro exposure.